Capricor Exosomes Program Update 2016

Capricor Therapeutics presented an update on its exosomes program as a next-generation regenerative medicine platform. The company holds exclusive worldwide license to CDC Exosomes technology from Cedars-Sinai Medical Center, with the first clinical indication targeted at ocular graft-vs-host disease (oGVHD).